Zero-profile Hyperlordotic Spacer for Cervical Deformity Correction: Case Presentation and Technical Note.

Cervical spine deformity (CSD) can negatively affect the health-related quality of life (HRQOL) of patients, particularly the elderly, thus representing a socioeconomic problem of increasing importance. While surgical deformity correction has been linked to improved HRQOL, no universally accepted consensus exists for the operative management of CSD. The authors demonstrate the feasibility of CSD correction, implementing anterior and posterior cervical osteotomies combined with the placement of multiple consecutive zero-profile hyperlordotic interbody spacers in a 55-year-old male with cervical kyphosis. This technique resulted in the satisfactory restoration of the patient's cervical alignment and significantly ameliorated his presenting symptoms. The patient demonstrated maintained cervical lordosis and he remained symptom-free at the one-year follow-up. The use of multiple consecutive zero-profile cervical interbody spacers can effectively and safely be utilized for the treatment of CSD. Further studies are needed to compare this technique with other standard surgeries used for CSD correction.

Role of minimally invasive surgery for adult spinal deformity in preventing complications.

With the aging population, there is a rising prevalence of degenerative spinal deformity and need of surgical care for these patients. Surgical treatment for adult spinal deformity (ASD) is often fraught with a high rate of complications. Minimally invasive surgery (MIS) has for the past decade been adopted by spine surgeons to treat ASD in the hopes of reducing access-related morbidity and perioperative complications. The benefits of MIS approach in general and recent development of MIS techniques to avoid long-term complications such as pseudoarthrosis or proximal junctional kyphosis are reviewed.

An Update on Translating Stem Cell Therapy for Stroke from Bench to Bedside.

With a constellation of stem cell sources available, researchers hope to utilize their potential for cellular repair as a therapeutic target for disease. However, many lab-to-clinic translational considerations must be given in determining their efficacy, variables such as the host response, effects on native tissue, and potential for generating tumors. This review will discuss the current knowledge of stem cell research in neurological disease, mainly stroke, with a focus on the benefits, limitations, and clinical potential.

In vivo animal stroke models: a rationale for rodent and non-human primate models.

On average, every four minutes an individual dies from a stroke, accounting for 1 out of every 18 deaths in the United States. Approximately 795,000 Americans have a new or recurrent stroke each year, with just over 600,000 of these being first attack [1]. There have been multiple animal models of stroke demonstrating that novel therapeutics can help improve the clinical outcome. However, these results have failed to show the same outcomes when tested in human clinical trials. This review will discuss the current in vivo animal models of stroke, advantages and limitations, and the rationale for employing these animal models to satisfy translational gating items for examination of neuroprotective, as well as neurorestorative strategies in stroke patients. An emphasis in the present discussion of therapeutics development is given to stem cell therapy for stroke.